TY - JOUR
T1 - A series of critically challenging case scenarios in moderate to severe psoriasis
T2 - A Delphi consensus approach
AU - Strober, Bruce
AU - Berger, Emily
AU - Cather, Jennifer
AU - Cohen, David
AU - Crowley, Jeffrey J.
AU - Gordon, Kenneth B.
AU - Gottlieb, Alice
AU - Horn, Elizabeth J.
AU - Kavanaugh, Arthur F.
AU - Korman, Neal J.
AU - Krueger, Gerald G.
AU - Leonardi, Craig L.
AU - Menter, Alan
AU - Schwartzman, Sergio
AU - Sobell, Jeffrey M.
AU - Young, Melodie
N1 - Funding Information:
Funding sources: Abbott, Amgen, Astellas, Celgene, Centocor, Galderma, Genentech, Pharmacare, and Stiefel. Dr Cather has received grants from Amgen. Dr Gottlieb has received research and/or educational grants from Centocor, Amgen, Wyeth, Immune Control, Celgene, Pharmacare, Incyte, and Abbott.
PY - 2009/7
Y1 - 2009/7
N2 - Clinical trials for systemic psoriasis therapy typically enroll healthy patients and exclude patients with cardiovascular disease, latent tuberculosis, liver disease, histories of malignancies, viral infections, children, and pregnant or breast-feeding women. Physicians often require guidance for optimum management of severe psoriasis in patients that have a combination of underlying disease states. To provide treatment recommendations for complex psoriasis scenarios, a consensus panel comprising 15 experts in psoriatic disease convened to review and discuss available evidence-based data and to arrive at a consensus for treatment options of difficult cases. An application of the Delphi Method was used to select case scenarios, provide medical treatment options, present the case study with existing medical evidence, and anonymously vote on treatment options. The top 10 treatment options were ranked and statistically analyzed to compare the differences between treatments. The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios.
AB - Clinical trials for systemic psoriasis therapy typically enroll healthy patients and exclude patients with cardiovascular disease, latent tuberculosis, liver disease, histories of malignancies, viral infections, children, and pregnant or breast-feeding women. Physicians often require guidance for optimum management of severe psoriasis in patients that have a combination of underlying disease states. To provide treatment recommendations for complex psoriasis scenarios, a consensus panel comprising 15 experts in psoriatic disease convened to review and discuss available evidence-based data and to arrive at a consensus for treatment options of difficult cases. An application of the Delphi Method was used to select case scenarios, provide medical treatment options, present the case study with existing medical evidence, and anonymously vote on treatment options. The top 10 treatment options were ranked and statistically analyzed to compare the differences between treatments. The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios.
UR - http://www.scopus.com/inward/record.url?scp=67649659930&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2009.03.017
DO - 10.1016/j.jaad.2009.03.017
M3 - Article
C2 - 19527820
AN - SCOPUS:67649659930
SN - 0190-9622
VL - 61
SP - S1-S46
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1 SUPPL. 1
ER -